Swedish Orphan Biovitrum Reports Q3 Revenue Growth and Upgrades FY2026 Outlook
Swedish Orphan Biovitrum AB (BIOVF) reported strong third-quarter financial results, highlighted by a 17.2% year-over-year increase in revenue to SEK 9.12 billion. The company achieved a Non-GAAP earnings per share (EPS) of SEK 6.96 and maintained stable operating cash flow at SEK 1,871 million. Following these results, the company has upgraded its full-year 2026 revenue guidance. Management now anticipates revenue growth in the high-teens to low-20s percentage range at constant exchange rates (CER), an increase from the previously projected mid-to-high-teens. The adjusted EBITA margin outlook remains steady, expected to fall within the mid-to-high 30% range.
Coverage
- ITT INC. - 8-K Filing
- Edwards Lifesciences Corp - 8-K Filing
- Entergy Non-GAAP EPS of $1.98 beats by $0.28; narrows FY2026 outlook
- AUTONATION, INC. - 8-K Filing
- Standard Chartered Reports Q3 Revenue Beat and Increases FY2026 Outlook
- Swedish Orphan Biovitrum Reports Q3 Revenue Growth and Upgrades FY2026 Outlook